TICKERNOMICS Sign up
Last Update: 2024-03-28 02:11:37
ImmunityBio Inc. ( IBRX ) https://immunitybio.com
5.12USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
IBRX
208.43%
SPY
32.74%
-80.88%
IBRX
SPY
92.93%
IBRX
0.00%
SPY
224.41%
IBRX
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
3434.84
3468.19
2.92
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-6.97
6177.77
-5.86
-43.60
0.00
-10.25
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-97726.83
100.00
-59905.13
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.27
-79.84
-208.37
0.00
Other Earnings and Cash Flow Stats:
ImmunityBio Inc. ( IBRX ) Net Income TTM ($MM) is -466.01
ImmunityBio Inc. ( IBRX ) Operating Income TTM ($MM) is -367.42
ImmunityBio Inc. ( IBRX ) Owners' Earnings Annual ($MM) is 18367.26
ImmunityBio Inc. ( IBRX ) Current Price to Owners' Earnings ratio is 0.19
ImmunityBio Inc. ( IBRX ) EBITDA TTM ($MM) is -355.89
ImmunityBio Inc. ( IBRX ) EBITDA Margin is -59905.13%
Capital Allocation:
ImmunityBio Inc. ( IBRX ) has paid 0.00 dividends per share and bought back -270.96697 million shares in the past 12 months
ImmunityBio Inc. ( IBRX ) has reduced its debt by 1113.138 million USD in the last 12 months
Capital Structure:
ImmunityBio Inc. ( IBRX ) Interest-bearing Debt ($MM) as of last quarter is 45
ImmunityBio Inc. ( IBRX ) Annual Working Capital Investments ($MM) are 46
ImmunityBio Inc. ( IBRX ) Book Value ($MM) as of last quarter is -586
ImmunityBio Inc. ( IBRX ) Debt/Capital as of last quarter is -8%
Other Balance Sheet Stats:
ImmunityBio Inc. ( IBRX ) has 265 million in cash on hand as of last quarter
ImmunityBio Inc. ( IBRX ) has 58 million of liabilities due within 12 months, and long term debt 1192 as of last quarter
ImmunityBio Inc. ( IBRX ) has 670 common shares outstanding as of last quarter
ImmunityBio Inc. ( IBRX ) has 0 million USD of preferred stock value
Academic Scores:
ImmunityBio Inc. ( IBRX ) Altman Z-Score is -8.10 as of last quarter
ImmunityBio Inc. ( IBRX ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
ImmunityBio Inc. ( IBRX ) largest shareholder is owning shares at 0.00 ($MM) value
Michael D Blaszyk(an insider) Bought 71915 shares of ImmunityBio Inc. ( IBRX ) for the amount of $197766.25 on 2023-06-05
72.58% of ImmunityBio Inc. ( IBRX ) is held by insiders, and 10.66% is held by institutions
ImmunityBio Inc. ( IBRX ) went public on 2015-07-28
Other ImmunityBio Inc. ( IBRX ) financial metrics:
FCF:-392.01
Unlevered Free Cash Flow:-410.58
EPS:-0.57
Operating Margin:-97726.83
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:65.13
Beta:0.00
Buffet's Owners Earnings:18367.26
Price to Owner's Earnings:0.19
About ImmunityBio Inc. ( IBRX ) :
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine technologies, toll-Like receptor activating adjuvants, natural killer cells, and damage-associated molecular patterns inducers. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company is based in San Diego, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.